Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

SAN DIEGO, April 15, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy. The study is being conducted by investigators from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Results from the analysis will be presented by Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals, at a late-breaking oral session on Sunday, April 17 at 7:55 a.m. PT at the 20th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE) in San Diego.

In the study, which has been ongoing for more than 10 years, researchers at the NIH are examining the effect of metreleptin on several metabolic abnormalities, including diabetes and hypertriglyceridemia (high levels of triglycerides in the bloodstream), in patients with rare inherited or acquired forms of lipodystrophy. Treatment with metreleptin resulted in robust reductions from baseline in both A1C and triglycerides. (A1C is a measure of average blood sugar over three months; triglycerides are the major form of fat stored in the body.) These improvements were apparent at four months and generally sustained for up to several years of treatment.

"Patients with rare forms of lipodystrophy are often affected by the disease early in life, are at high risk of acute and chronic complications and, currently, have very limited therapeutic options," said Dr. Weyer. "The results of our analysis reaffirm the potential of metreleptin as an important advance for people living with this chronic and often debilitating metabolic disease. We continue to work diligently toward bringing this potential
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... und TÜBINGEN, Deutschland, 5. März 2015 ... Stiftung und das deutsche biopharmazeutische Unternehmen CureVac ... Millionen Euro (52 Millionen US-Dollar) in CureVac ... der medizinisch angewandten Messenger-RNA (mRNA). Auf Basis ... zur Behandlung von Krankheiten und zum Schutz ...
(Date:3/5/2015)... 5, 2015 Bayer HealthCare announced today that ... Cancer Foundation of the American Society of Clinical Oncology ... technology platform designed to unlock vast quantities of information ... "Bayer is proud to join ASCO and ... Big Data to help people whose lives have been ...
(Date:3/5/2015)... March 5, 2015  Medical Diagnostic Laboratories, L.L.C., ... high complexity, state-of-the-art, automated DNA-based molecular analyses, announces ... (HPV) testing which utilizes cutting edge technology, including ... year, approximately 12,000 women are diagnosed with cervical ... . Genital Human Papillomaviruses (HPV) are a group ...
Breaking Medicine Technology:Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3
... Chimerix, Inc., a biotechnology company developing orally-available antiviral ... the Board and Chief Scientific Officer, will participate on ... Therapeutics Conference on July 22nd, 2011, 10:30 am ET. ... Club in Washington, D.C. on July 20-22, 2011, and ...
... July 20, 2011 Concentric Medical, Inc., the global ... patients, today announced the launch of the expanded family ... the V 2.0 Soft and V 3.0 Soft, through ... Merci Retrievers® are now approved and reimbursed in Japan. ...
Cached Medicine Technology:Chimerix to Present at Infocast's 9th Annual Biodefense Vaccines & Therapeutics Conference 2Chimerix to Present at Infocast's 9th Annual Biodefense Vaccines & Therapeutics Conference 3Concentric Medical Launches Full Family of Merci Retrievers® in Japan 2Concentric Medical Launches Full Family of Merci Retrievers® in Japan 3
(Date:3/6/2015)... (PRWEB) March 06, 2015 As the ... to be discussed, Ford & Associates Nationwide Legal Services, ... January 2015 filed lawsuit: Verduzco v. Daiichi Sankyo, Inc., ... of California. , “In light of a recently ... used Benicar to evaluate and explore the Mayo Clinic's ...
(Date:3/5/2015)... In 2014, the FDA approved 44 drugs, with ... scoring 4 drug approvals in the USA. The infectious ... drug products, followed by oncology therapy with 18% of ... CDK inhibitors keep on attracting large-cap pharmacos. Nivolumab and ... metastatic melanoma, and at present, they are being investigated ...
(Date:3/5/2015)... March 05, 2015 This week, ... in low-cost laminate flooring products, initiating widespread ... of eco-friendly building materials made primarily from bamboo, ... testing all their flooring products for volatile organic ... Benchmark International (BMH). Results from formaldehyde ...
(Date:3/5/2015)... NY (PRWEB) March 05, 2015 ... forward in a Pennsylvania mass tort litigation currently ... where a jury has begun hearing testimony in ... the atypical antipsychotic medication can cause gynecomastia, or ... case in question was filed on behalf of ...
(Date:3/5/2015)... RI (PRWEB) March 05, 2015 Rhode Island ... third year in a row to support the Providence College ... The donation covered the purchase of the ‘Think Pink’ uniforms, ... against Big East Conference opponent DePaul University at Alumni Hall/Mullaney ... to continue our support of the PC women’s basketball’s ‘Pink ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2
... WEDNESDAY, Dec. 8 (HealthDay News) -- Omega-3 fatty acids may ... fatty acid called DHA is used in the right ratio ... suggests. The researchers analyzed the results of some 15 ... commonly found in oily fish or in fish oil supplements ...
... a key role in the prevention of the painful ... new research from the University of Pennsylvania School of ... exercise limits a worsening of symptoms among women who ... of long-running advice that breast cancer survivors should avoid ...
... Eastern Virginia Medical School researchers have identified a ... people with Autism Spectrum Disorders (ASD), an aspect of ... of life. "Persons with Autism Spectrum Disorders ... unpleasant. They often don,t understand what other people are ...
... breakthrough? See what the experts have to say ... Perspectives on Psychological Science . Neuroimaging: ... Special Section on fMRI ( http://pps.sagepub.com/content/5/6/714.full ) ... widespread interest following the publication of Vul et ...
... News) -- One third of lesbian, gay, bisexual ... lifetime, but most of them are mentally strong, new ... of Illinois at Chicago conducted psychiatric interviews with 246 ... for major depression, post-traumatic stress disorder (PTSD), conduct disorder ...
... By Dennis Thompson HealthDay Reporter , WEDNESDAY, Dec. ... to sudden infant death syndrome a little more than two months ... The twins were born seven weeks early, on Feb. ... early arrival, said Glover, now 40 and living in Stone Mountain, ...
Cached Medicine News:Health News:Certain Formulations of Omega-3s Might Help With Depression 2Health News:Certain Formulations of Omega-3s Might Help With Depression 3Health News:Weightlifting slashes lymphedema risk after breast cancer treatment 2Health News:Weightlifting slashes lymphedema risk after breast cancer treatment 3Health News:Autism breakthrough: Researchers identify possible treatment for impaired sociability 2Health News:fMRI special section of Perspectives on Psychological Science 2Health News:fMRI special section of Perspectives on Psychological Science 3Health News:Researchers Assess Gay Youths' Mental Health 2Health News:Mother Talks of the Anger, Confusion and Grief of a SIDS Death 2Health News:Mother Talks of the Anger, Confusion and Grief of a SIDS Death 3
... Low Profile Ergonomic Design ... of neuroendoscopes offers rigid working ... steerable tip. The rigid scope ... approach to the target. The ...
... new biological material produced from ... implant, lyoplant can absorb in ... implant material with the recipient's ... minimizes suture channels, resulting in ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Medicine Products: